Page last updated: 2024-09-03

ly 274614 and clebopride

ly 274614 has been researched along with clebopride in 1 studies

Compound Research Comparison

Studies
(ly 274614)
Trials
(ly 274614)
Recent Studies (post-2010)
(ly 274614)
Studies
(clebopride)
Trials
(clebopride)
Recent Studies (post-2010) (clebopride)
960151161711

Protein Interaction Comparison

ProteinTaxonomyly 274614 (IC50)clebopride (IC50)
AcetylcholinesteraseHomo sapiens (human)0.89
D(2) dopamine receptorRattus norvegicus (Norway rat)0.017
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.6026

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Awere, S; Blackman, A; Leander, JD; Moore, NA1

Other Studies

1 other study(ies) available for ly 274614 and clebopride

ArticleYear
NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
    European journal of pharmacology, 1993, Jun-11, Volume: 237, Issue:1

    Topics: Animals; Benzamides; Benzazepines; Catalepsy; Chlordiazepoxide; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Haloperidol; Isoquinolines; Male; Rats; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate

1993